KINDSTAR GLOBAL (09960) announced its annual performance, with revenue of 0.934 billion yuan, an increase of 0.65% year-on-year. Revenue from the oncology sector achieved a significant increase of 106.2%.

KINDSTAR GLOBAL (09960) announced its annual results for the year ending December 31, 2025, with the group achieving revenue of 934 million yuan, an increase of 0.65% year-on-year; a net loss of 55.149 million yuan, a decrease of 9.12% year-on-year; and a loss per share of 5.92 cents. The announcement stated that against the backdrop of the deep adjustment period in the third-party medical testing industry, with the continuous deepening of medical insurance cost control policies and the accelerated promotion of mutual recognition of test results, both ends of the traditional testing business have faced temporary pressures on volume and price. In response to the industry changes, the group adheres to the strategic focus of "specialized testing + precision medicine": on one hand, relying on technological barriers, the core specialty businesses such as blood testing have maintained a stable foundation; on the other hand, through strategic acquisitions, it rapidly entered the physical tumor early screening blue ocean market, driving a significant 106.2% growth in revenue in the tumor segment; at the same time, the company actively expanded its research services and contract research organization (CRO) segment, with revenue in this segment growing by 33.4% year-on-year during the reporting period. The improvement in performance mainly reflects the repair of the operating fundamentals and the growth of fair value changes in income, partially offset by strategic investment costs and credit risk provisions: Operational efficiency: The company actively implemented cost reduction and efficiency improvement measures, continuously optimizing its business structure. The results of these efforts gradually became apparent, and the operating fundamentals showed a stable and improving trend; Fair value changes in income: Compared with the same period last year, the fair value changes in income of the funds in which the company participated significantly increased; Credit risk provisions: New provisions for expected credit losses on accounts receivable were made during the reporting period; Strategic investment: In response to external environmental changes, the company accelerated the expansion of new business sectors, including integration costs arising from the acquisition of Guangzhou Benchmark Medical Limited Liability Company and Guangzhou Kangcheng Weiye Biological Technology Co., Ltd. (collectively referred to as "acquired subsidiaries" or "Benchmark Medical"), as well as the phased investments made in the expansion process of the CRO segment. Taken together, the net loss for the reporting period decreased compared to the same period last year.